Physician profile
Mark J Hepp
NPI 1194714758
$398.82
in general payments reported to CMS, 2019-2025
10 companies · $50.01 in 2025
The $50.01 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $66.85 · 2022: $52.57 · 2023: $13.11 · 2025: $50.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $69.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $67.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $65.68 | 2022-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $49.38 | 2019-2020 | |
| Boston Scientific Corporation | $35.48 | 2019-2020 | |
| Cleerly, INC. | $28.18 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Csl Behring | $27.13 | 2019 | |
| Pfizer INC. | $21.83 | 2025 | |
| Astellas Pharma US INC | $21.43 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hepp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.